MCG
MRNA icon

McCollum Christoferson Group’s Moderna MRNA Stock Holding History

McCollum Christoferson Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-650
Closed -$250K – 77
2021
Q3 		$250K Buy
+650
New +$240K 0.06% 63

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

McCollum Christoferson Group's MRNA Position: Q4 2021 in Review

McCollum Christoferson Group sold out of Moderna (MRNA) in Q4 2021, closing a stake of 650 shares — an estimated $250K sold.

McCollum Christoferson Group first reported a position in MRNA in Q3 2021 and held it in 1 quarter. The position peaked at $250K in Q3 2021. 1,110 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

  • McCollum Christoferson Group reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
  • McCollum Christoferson Group sold 650 Moderna shares in Q4 2021, an estimated $250K.
  • McCollum Christoferson Group first reported a position in Moderna in Q3 2021 and held it in 1 quarter.
  • McCollum Christoferson Group's Moderna position peaked at $250K in Q3 2021.
  • 1,110 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on McCollum Christoferson Group's 13F filing for Q4 2021, filed 9 Feb 2022.